Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down to $33.55

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report)'s stock price gapped down before the market opened on Monday . The stock had previously closed at $33.55, but opened at $30.58. Supernus Pharmaceuticals shares last traded at $32.41, with a volume of 63,095 shares traded.

Wall Street Analyst Weigh In

Separately, Piper Sandler dropped their price objective on shares of Supernus Pharmaceuticals from $45.00 to $41.00 and set an "overweight" rating on the stock in a report on Wednesday, February 28th.

Supernus Pharmaceuticals Trading Down 6.3 %

The firm's fifty day moving average price is $30.83 and its 200-day moving average price is $28.37.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by ($0.39). Supernus Pharmaceuticals had a return on equity of 0.14% and a net margin of 0.22%. The company had revenue of $164.30 million for the quarter, compared to the consensus estimate of $155.03 million. During the same quarter in the previous year, the firm posted $0.43 EPS. The business's revenue for the quarter was down 1.8% compared to the same quarter last year. On average, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.16 earnings per share for the current year.

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 14,491 shares of the company's stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $35.31, for a total value of $511,677.21. Following the sale, the vice president now owns 8,570 shares of the company's stock, valued at $302,606.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, VP Padmanabh P. Bhatt sold 14,491 shares of the company's stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $35.31, for a total value of $511,677.21. Following the sale, the vice president now owns 8,570 shares of the company's stock, valued at $302,606.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 5,000 shares of the company's stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $30.21, for a total transaction of $151,050.00. Following the completion of the sale, the vice president now directly owns 8,570 shares in the company, valued at approximately $258,899.70. The disclosure for this sale can be found here. Insiders have sold a total of 43,739 shares of company stock valued at $1,450,713 over the last quarter. 8.76% of the stock is owned by company insiders.

Institutional Trading of Supernus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth about $1,049,000. Vanguard Group Inc. grew its stake in Supernus Pharmaceuticals by 0.5% during the third quarter. Vanguard Group Inc. now owns 6,072,180 shares of the specialty pharmaceutical company's stock worth $167,410,000 after buying an additional 28,711 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in Supernus Pharmaceuticals by 8.6% during the third quarter. Loomis Sayles & Co. L P now owns 1,730,269 shares of the specialty pharmaceutical company's stock worth $47,703,000 after buying an additional 136,964 shares during the last quarter. Trust Point Inc. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $325,000. Finally, QRG Capital Management Inc. acquired a new position in shares of Supernus Pharmaceuticals during the third quarter worth approximately $416,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.